The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Abstract
BACKGROUND: Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα-interleukin-13Rα1 heterodimer receptor signaling complex. METHODS: We conducted two identically designed, 52-week, randomized, double-blind, placebo-controlled, phase 3 trials; both trials included a 16-week induction period and a 36-week maintenance period. Eligible patients with moderate-to-severe atopic dermatitis (adults [≥18 years of age] and adolescents [12 to <18 years of age, weighing ≥40 kg]) were randomly assigned in a 2:1 ratio to receive either lebrikizumab at a dose of 250 mg (loading dose of 500 mg at baseline and week 2) or placebo, administered subcutaneously every 2 weeks. Outcomes for the induction period were assessed up to 16 weeks and are included in this report. The primary outcome was an Investigator's Global Assessment (IGA) score of 0 or 1 (indicating clear or almost clear skin; range, 0 to 4 [severe disease]) with a reduction (indicating improvement) of at least 2 points from baseline at week 16. Secondary outcomes included a 75% improvement in the Eczema Area and Severity Index score (EASI-75 response) and assessments of itch and of itch interference with sleep. Safety was also assessed. RESULTS: In trial 1, the primary outcome was met in 43.1% of 283 patients in the lebrikizumab group and in 12.7% of 141 patients in the placebo group (P<0.001); an EASI-75 response occurred in 58.8% and 16.2%, respectively (P<0.001). In trial 2, the primary outcome was met in 33.2% of 281 patients in the lebrikizumab group and in 10.8% of 146 patients in the placebo group (P<0.001); an EASI-75 response occurred in 52.1% and 18.1%, respectively (P<0.001). Measures of itch and itch interference with sleep indicated improvement with lebrikizumab therapy. The incidence of conjunctivitis was higher among patients who received lebrikizumab than among those who received placebo. Most adverse events during the induction period were mild or moderate in severity and did not lead to trial discontinuation. CONCLUSIONS: In the induction period of two phase 3 trials, 16 weeks of treatment with lebrikizumab was effective in adolescents and adults with moderate-to-severe atopic dermatitis. (Funded by Dermira; ADvocate1 and ADvocate2 ClinicalTrials.gov numbers, NCT04146363 and NCT04178967, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationLangan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., Berger, T. G., Bergman, J. N., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.010 · Cited by 1,277
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885
Self-citationThe burden of atopic dermatitis: summary of a report for the National Eczema Association.
Drucker, A. M., Wang, A. R., Li, W.-Q., Sevetson, E., Block, J. K., & Qureshi, A. A. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.07.012 · Cited by 720
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14888 · Cited by 684
Patient burden and quality of life in atopic dermatitis in US adults
Silverberg, J. I., Gelfand, J. M., Margolis, D. J., Boguniewicz, M., Fonacier, L., Grayson, M. H., Simpson, E. L., Ong, P. Y., & Chiesa Fuxench, Z. C. (2018) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2018.07.006 · Cited by 648
Self-citationThe immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman-Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 642
Self-citationWollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J. ‐., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19574 · Cited by 638
Self-citationPathophysiology of atopic dermatitis: Clinical implications
Kim, J., Kim, B. E., & Leung, D. Y. M. (2019) · Allergy and Asthma Proceedings · doi:10.2500/aap.2019.40.4202 · Cited by 635
The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017*
Laughter, M. R., Maymone, M. B. C., Mashayekhi, S., Arents, B. W. M., Karimkhani, C., Langan, S. M., Dellavalle, R. P., & Flohr, C. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19580 · Cited by 621
Tsoi, L. C., Rodriguez, E., Degenhardt, F., Baurecht, H., Wehkamp, U., Volks, N., Szymczak, S., Swindell, W. R., Sarkar, M. K., Raja, K., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.12.018 · Cited by 469
Comorbidities and the impact of atopic dermatitis
Silverberg, J. I. (2019) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2019.04.020 · Cited by 431
Self-citationTreatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Wollenberg, A., Howell, M. D., Guttman-Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R., & van der Merwe, R. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.05.029 · Cited by 409
Self-citationSignificance of Skin Barrier Dysfunction in Atopic Dermatitis
Kim, B. E., & Leung, D. Y. M. (2018) · Allergy, Asthma & Immunology Research · doi:10.4168/aair.2018.10.3.207 · Cited by 393
Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
Bieber, T. (2020) · Allergy · doi:10.1111/all.13954 · Cited by 382
Prevalence of contact allergy in the general population in different European regions
Diepgen, T. L., Ofenloch, R. F., Bruze, M., Bertuccio, P., Cazzaniga, S., Coenraads, P.-J., Elsner, P., Goncalo, M., Svensson, Å., & Naldi, L. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14167 · Cited by 355
Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
Renert-Yuval, Y., Thyssen, J. P., Bissonnette, R., Bieber, T., Kabashima, K., Hijnen, D., & Guttman-Yassky, E. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.013 · Cited by 350
Self-citationGuttman-Yassky, E., Blauvelt, A., Eichenfield, L. F., Paller, A. S., Armstrong, A. W., Drew, J., Gopalan, R., & Simpson, E. L. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.0079 · Cited by 341
Self-citationSimpson, E. L., Flohr, C., Eichenfield, L. F., Bieber, T., Sofen, H., Taïeb, A., Owen, R., Putnam, W., Castro, M., DeBusk, K., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.017 · Cited by 331
Self-citationAssociation of Atopic Dermatitis With Sleep Quality in Children
Ramirez, F. D., Chen, S., Langan, S. M., Prather, A. A., McCulloch, C. E., Kidd, S. A., Cabana, M. D., Chren, M.-M., & Abuabara, K. (2019) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2019.0025 · Cited by 320
Persistence of atopic dermatitis (AD): A systematic review and meta-analysis
Kim, J. P., Chao, L. X., Simpson, E. L., & Silverberg, J. I. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.05.028 · Cited by 273
Self-citationEpidemiology of adult atopic dermatitis
Sacotte, R., & Silverberg, J. I. (2018) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2018.05.007 · Cited by 231
Self-citationAn Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease
Ungar, B., Garcet, S., Gonzalez, J., Dhingra, N., Correa da Rosa, J., Shemer, A., Krueger, J. G., Suarez-Farinas, M., & Guttman-Yassky, E. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.09.037 · Cited by 213
Self-citationLee, H. H., Patel, K. R., Singam, V., Rastogi, S., & Silverberg, J. I. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.05.1241 · Cited by 208
Self-citationNew treatments in atopic dermatitis
Puar, N., Chovatiya, R., & Paller, A. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.08.016 · Cited by 199
Rerknimitr, P., Otsuka, A., Nakashima, C., & Kabashima, K. (2017) · Inflammation and Regeneration · doi:10.1186/s41232-017-0044-7 · Cited by 187
Simpson, E. L., Gooderham, M., Wollenberg, A., Weidinger, S., Armstrong, A. W., Soung, J., Ferrucci, S. M., Lima, R. G., Witte, M. M., Xu, W., et al. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.5534 · Cited by 182
Self-citationRenert-Yuval, Y., Del Duca, E., Pavel, A. B., Fang, M., Lefferdink, R., Wu, J., Diaz, A., Estrada, Y. D., Canter, T., Zhang, N., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.001 · Cited by 168
Self-citationMoyle, M., Cevikbas, F., Harden, J. L., & Guttman‐Yassky, E. (2019) · Experimental Dermatology · doi:10.1111/exd.13911 · Cited by 163
Self-citationEczema, atopy and allergen exposure in adults: a population‐based study
Harrop, J., Chinn, S., Verlato, G., Olivieri, M., Norbäck, D., Wjst, M., Janson, C., Zock, J. ‐., Leynaert, B., Gislason, D., et al. (2007) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2007.02679.x · Cited by 162
Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis
Slattery, M. J., Essex, M. J., Paletz, E. M., Vanness, E. R., Infante, M., Rogers, G. M., & Gern, J. E. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.05.003 · Cited by 159
Sleep disorders and atopic dermatitis: A 2-way street?
Chang, Y.-S., & Chiang, B. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.005 · Cited by 153
Winthrop, K. L., Novosad, S., Baddley, J. W., Calabrese, L. H., Chiller, T. M., Polgreen, P. M., Bartalesi, F., Lipman, M. C. I., Xavier Mariette, A., Lortholary, O., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207841 · Cited by 142
Wollenberg, A., Beck, L. A., de Bruin-Weller, M. S., Simpson, E. L., Imafuku, S., Boguniewicz, M., Zachariae, R., Olsen, C. K., & Thyssen, J. P. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20810 · Cited by 90
Self-citationPrevalence of atopic dermatitis determined by clinical examination in Japanese adults
Saeki, H., Tsunemi, Y., Fujita, H., Kagami, S., Sasaki, K., Ohmatsu, H., Watanabe, A., & Tamaki, K. (2006) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2006.00187.x · Cited by 87
Andersen, L. Ø., Nyeland, M. E., & Nyberg, F. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18296 · Cited by 84
Suicidal risks with psoriasis and atopic dermatitis: Systematic review and meta-analysis
Pompili, M., Bonanni, L., Gualtieri, F., Trovini, G., Persechino, S., & Baldessarini, R. J. (2020) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2020.110347 · Cited by 68
A Clinician’s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis
Agnihotri, G., Shi, K., & Lio, P. (2019) · Drugs in R&D · doi:10.1007/s40268-019-00288-x · Cited by 66
Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis
Loh, T. Y., Hsiao, J. L., & Shi, V. Y. (2020) · Journal of Asthma and Allergy · doi:10.2147/jaa.s211032 · Cited by 57
Selective IL-13 inhibitors for the treatment of atopic dermatitis
Gonçalves, F., Freitas, E., & Torres, T. R. (2021) · Drugs in Context · doi:10.7573/dic.2021-1-7 · Cited by 56
Atopic dermatitis in adolescence
Ricci, G., Bellini, F., Dondi, A., Patrizi, A., & Pession, A. (2011) · Dermatology Reports · doi:10.4081/dr.2012.e1 · Cited by 46
IL‐4 and IL‐13 both contribute to the homeostasis of human conjunctival goblet cells in vitro
Hansen, P. M., Tollenaere, M. A. X., Hedengran, A., Heegaard, S., Amoudruz, P., Røpke, M. A., Thyssen, J. P., Kolko, M., & Norsgaard, H. (2022) · Allergy · doi:10.1111/all.15326 · Cited by 42
Sims, J. T., Chang, C.-Y., Higgs, R. E., Engle, S., Liu, Y., Sissons, S. E., Rodgers, G. H., Simpson, E. L., Silverberg, J. I., Forman, S. B., et al. (2021) · Experimental Dermatology · doi:10.1111/exd.14389 · Cited by 39
Self-citationInhibition of IL-13: A New Pathway for Atopic Dermatitis
Ratnarajah, K., Le, M., Muntyanu, A., Mathieu, S., Nigen, S., Litvinov, I. V., Jack, C. S., & Netchiporouk, E. (2020) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475420982553 · Cited by 36
Wulur, I. H., Horn, R. V., Ryuzoji, A. F., et al. (2022) · doi:10.26226/m.62fa0091165d7b0019592ac8 · Cited by 3
Ocular conjunctivitis in biological therapies for atopic dermatitis
Nguyen, R. (2022) · British Journal of Dermatology · doi:10.1111/bjd.20945 · Cited by 2
Cited by
Guttman-Yassky, E., Renert-Yuval, Y., & Brunner, P. M. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02519-4 · Cited by 321
Self-citationImmune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
Seremet, T., Di Domizio, J., Girardin, A., Yatim, A., Jenelten, R., Messina, F., Saidoune, F., Schlapbach, C., Bogiatzi, S., Minisini, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54559-6 · Cited by 57
Abdel-Mageed, H. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01642-z · Cited by 45
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Bernardo, D., Bieber, T., & Torres, T. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00793-5 · Cited by 43
Airways Type-2 Related Disorders: Multiorgan, Systemic or Syndemic Disease?
Giombi, F., Pace, G. M., Pirola, F., Cerasuolo, M., Ferreli, F., Mercante, G., Spriano, G., Canonica, G. W., Heffler, E., Ferri, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020730 · Cited by 25
Metadata
- Authors
- Silverberg, J. I., Guttman-Yassky, E., Thaçi, D., Irvine, A. D., Stein Gold, L., Blauvelt, A., Simpson, E. L., Chu, C.-Y., Liu, Z., Gontijo Lima, R., Pillai, S. G., & Seneschal, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-03-23
- Volume
- 388
- Issue
- 12
- Pages
- 1080-1091
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4324311526
- Cited by
- 345
- References
- 50
- FWCI
- 78.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.